| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 4714 | 2010 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 3294 | 2013 |
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... N Engl j Med 371, 2167-2177, 2014 | 2532 | 2014 |
| Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247, 2009 | 2013 | 2009 |
| Ceritinib in ALK-rearranged non–small-cell lung cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... N Engl j med 370, 1189-1197, 2014 | 1528 | 2014 |
| Crizotinib in ROS1-rearranged non–small-cell lung cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 1486 | 2014 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1318 | 2012 |
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1167 | 2012 |
| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 1064 | 2015 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1037 | 2012 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1014 | 2011 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 849 | 2010 |
| Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ... Journal of clinical oncology 28 (27), 4142, 2010 | 735 | 2010 |
| Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American … NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Archives of pathology & laboratory medicine 142 (3), 321-346, 2018 | 716 | 2018 |
| Rociletinib in EGFR-mutated non–small-cell lung cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 703 | 2015 |
| Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ... Journal of Clinical Oncology 33 (17), 1881, 2015 | 535 | 2015 |
| Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with … SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, ... Journal of thoracic oncology 6 (5), 942-946, 2011 | 425 | 2011 |
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib JK Lennerz, EL Kwak, A Ackerman, M Michael, SB Fox, K Bergethon, ... Journal of clinical oncology 29 (36), 4803, 2011 | 424 | 2011 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 363 | 2016 |
| Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ... The Lancet Oncology 18 (12), 1590-1599, 2017 | 361 | 2017 |
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterVerified email at MSKCC.org
